Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poractant alfa
- Development stage
- Approved
- Lead developer
- Chiesi
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intratracheal
01
Overview
Poractant alfa is a pulmonary surfactant derived from porcine lung extract, composed primarily of phospholipids (mainly phosphatidylcholine and dipalmitoylphosphatidylcholine) and hydrophobic surfactant-associated proteins SP-B and SP-C. It is used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants with endogenous surfactant deficiency. Poractant alfa acts by reducing surface tension at the air-liquid interface within the alveoli, thereby stabilizing them against collapse during breathing, improving lung compliance, and enhancing respiratory gas exchange. The drug is administered intratracheally and rapidly adsorbs to form a stable monolayer on the alveolar surface[1][2][3][4][5][6]. **Developers:** Chiesi Farmaceutici **Manufacturers:** Chiesi Farmaceutici
- Brand names
- Curosurf
- Other names
- poractant
02
Targets
SFTPB (Pulmonary surfactant protein B)
Beyond the preview
Go deeper on Poractant alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poractant alfa.